Loading...

ProPhase Labs, Inc.

PRPHNASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.33
$-0.01(-1.88%)

ProPhase Labs, Inc. (PRPH) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for ProPhase Labs, Inc. (PRPH), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
-84.75%
84.75%
Operating Income Growth
-78.73%
78.73%
Net Income Growth
-217.98%
217.98%
Operating Cash Flow Growth
-54.55%
54.55%
Operating Margin
-900.03%
900.03%
Gross Margin
60.45%
60.45%
Net Profit Margin
-1241.08%
1241.08%
ROE
-230.18%
230.18%
ROIC
-183.13%
183.13%

ProPhase Labs, Inc. (PRPH) Income Statement & Financial Overview

Access detailed annual and quarterly income data for ProPhase Labs, Inc. PRPH financial performance.

MetricQ4 2024Q3 2024Q2 2024Q1 2024
Revenue-$2.48M$3.15M$2.47M$3.63M
Cost of Revenue-$3.41M$3.31M$2.95M$4.07M
Gross Profit$924000.00-$165000.00-$476000.00-$433000.00
Gross Profit Ratio-$0.37-$0.05-$0.19-$0.12
R&D Expenses$61000.00$122000.00$139000.00$272000.00
SG&A Expenses$15.43M$7.65M$7.21M$7.59M
Operating Expenses$15.49M$7.77M$7.35M$7.87M
Total Costs & Expenses$12.08M$11.08M$10.30M$11.93M
Interest Income$0.00$0.00$0.00$0.00
Interest Expense$1.03M$1.16M$643000.00$515000.00
Depreciation & Amortization$613000.00$2.51M$1.73M$1.80M
EBITDA-$14.32M-$5.43M-$6.07M-$6.52M
EBITDA Ratio$5.76-$1.73-$2.45-$1.79
Operating Income-$14.57M-$7.94M-$7.83M-$8.30M
Operating Income Ratio$5.86-$2.52-$3.16-$2.28
Other Income/Expenses (Net)-$1.40M-$1.16M-$613000.00-$533000.00
Income Before Tax-$15.96M-$9.10M-$8.44M-$8.83M
Income Before Tax Ratio$6.43-$2.89-$3.41-$2.43
Income Tax Expense$14.56M-$2.51M-$2.29M-$2.57M
Net Income-$34.36M-$6.59M-$6.15M-$6.26M
Net Income Ratio$13.83-$2.09-$2.49-$1.72
EPS-$1.80-$0.35-$0.33-$0.35
Diluted EPS-$1.80-$0.35-$0.33-$0.35
Weighted Avg Shares Outstanding$20.46M$19.08M$18.89M$18.05M
Weighted Avg Shares Outstanding (Diluted)$20.46M$19.08M$18.89M$18.05M

Over the last four quarters, ProPhase Labs, Inc. achieved steady financial progress, growing revenue from $3.63M in Q1 2024 to -$2.48M in Q4 2024. Gross profit stayed firm with margins at -37% in Q4 2024 versus -12% in Q1 2024. Operating income totaled -$14.57M in Q4 2024, maintaining a 586% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$14.32M. Net income dropped to -$34.36M, with EPS at -$1.80. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;